** TX STATUS REPORT ** AS OF OCT 04 2002 15:20 PAGE.01

09

THOMPSON COBURN LLP 3

	DATE	TIME	TO/FROM	MODE	MIN/SEC	PGS	JOB#	STATUS
15	10/04	15:19	USPTO	EC—S	01'46"	010	148	OK

THOMPSON COBURN

Thompson Coburn LLP
Attorneys at Law

One Mercantile Center
St. Louis, Missouri 63101-1693
314-552-6000
FAX 314-552-7000
www.thompsoncoburn.com

Facsimile

FOR IMMEDIATE DELIVERY

To	Firm Name	Phone	Fax
Examiner Ram Shukla	US PTO Group Art Unit 1632		703-872-9307

From: DANIEL KASTEN

Date: October 4, 2002

Message:

Atty/Client/Matter No.: 30[illegible]

Total Number of Pages, including this page: 10

If you do not receive all of the pages, please call 314-552-6000 as soon as possible.

Thank you,
Fax Department - Operator: [illegible] Time of Transmittal: 3:17 A.M./P.M.

DOCKETED
DEC 0 4 2002
Thompson Coburn LLP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#22/F NO
Yita
6/21/03

St. Louis, Missouri
October 4, 2002

CERTIFICATE OF FACSIMILE

I hereby certify that this document is being transmitted to the U.S. Patent and Trademark Office via facsimile to fax no. (703) 872-9307 on October 4, 2002.

Daniel S. Kasten
Attorney for Applicant(s)
Registration No.: 45,363

Daniel S. Kasten
Reg. No. 45363
Thompson Coburn LLP
#1 US Bank Plaza
St. Louis, MO 63101
314-552-6305

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Wold, William S.M.	**Group No.:**	1632
Serial No.:	09/111,911	**Atty. Docket No.:**	66153-5587
Filed:	July 8, 1998		
For:	Inhibiting Apoptosis with Adenovirus RID Protein	**Examiner:**	Ram R. Shukla, Ph.D.

Commissioner of Patents and Trademarks
Washington, DC 20231

1983966

AMENDMENT AND RESPONSE

HONORABLE SIR:

Responsive to the official communication of September 13, 2002, Applicant submits the following Amendments and Remarks.

It is not believed that extensions of time are required beyond those, which may otherwise be provided for in documents accompanying this Amendment. However, in the event that additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned for under 37 C.F.R. § 1.136(a), and any fees required therefore are hereby authorized to be charged to our Deposit Account 20-0823.

Please amend the above-identified application as set forth below.

In The Claims:

Cancel claims 7, 10 and 13.

26. (Amended) [The method of claim 13] A method for decreasing the rejection of transplanted cells comprising contacting the cells ex vivo with a recombinant adenovirus comprising a polynucleotide encoding a RIDα-S polypeptide, a RIDα-L polypeptide and a RIDβ polypeptide, as disclosed in SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:4, wherein (a) the polynucleotide is operably linked to a cytomegalovirus ("CMV") promoter, (b) the adenovirus enters the cell and delivers the polynucleotide to the cell, (c) the RIDα-S polypeptide, RIDα-L polypeptide and RIDβ polypeptide are expressed in the cell in an amount sufficient to inhibit apoptosis of the cell, (d) the cell expresses Fas, DR3, TRAIL-R1, or TRAIL-R2, (e) the adenovirus lacks at least one functional E1 gene and (f) the rejection is mediated by Fas receptor activity; wherein the